Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22091420 | 0.85 | BRD4 (0.56) | SMN1; SMN2ALDH1A1BRD4MAPT | |
| SCHEMBL24131793 | 0.83 | MAPK10 (0.52) | SMN1; SMN2ALDH1A1LMNAGAA | |
| SCHEMBL13702155 | 0.82 | BRD4 (0.55) | NAMPTSMN1; SMN2ALDH1A1POLBGAA | |
| SCHEMBL22091424 | 0.79 | MEN1 (0.51) | SMN1; SMN2ALDH1A1POLBPTGS2GAA | |
| SCHEMBL23520473 | 0.79 | ALDH1A1 (0.42) | NAMPTSMN1; SMN2ALDH1A1POLBLMNA | |
| SCHEMBL23520519 | 0.78 | CYP17A1 (0.49) | SMN1; SMN2ALDH1A1POLBLMNAGAA | |
| SCHEMBL23520523 | 0.78 | ALDH1A1 (0.53) | NAMPTSMN1; SMN2ALDH1A1POLBCYP2C19 | |
| SCHEMBL22091411 | 0.77 | ALDH1A1 (0.45) | NAMPTSMN1; SMN2ALDH1A1CYP2C19LMNA | |
| SCHEMBL22091425 | 0.77 | ALDH1A1 (0.45) | NAMPTSMN1; SMN2ALDH1A1CYP2C19LMNA | |
| SCHEMBL22091419 | 0.77 | SIRT2 (0.41) | SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115003658-B | Compounds and their use for the treatment of alpha1Use of antitrypsin deficiency | 森特萨制药(英国)有限公司 | 2024-07-23 | — | — | CN | claimed |
| EP-4073043-B1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY | CENTESSA PHARMACEUTICALS UK LTD (GB) | 2024-04-03 | — | — | EP | claimed |
| CN-115003658-A | Compounds and their use in the treatment of alpha 1 Use against trypsin deficiency | Z因子有限公司 | 2022-09-02 | — | — | CN | claimed |
| CN-115003658-B | Compounds and their use for the treatment of alpha1Use of antitrypsin deficiency | 森特萨制药(英国)有限公司 | 2024-07-23 | — | — | CN | disclosed |
| US-20230102488-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY | OXFORD FINANCE LLC | 2023-03-30 | — | — | US | disclosed |
| WO-2022263829-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY | Z Factor Limited (GB) | 2022-12-22 | — | — | WO | disclosed |
| EP-4073043-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY | Z Factor Limited (GB) | 2022-10-19 | — | — | EP | disclosed |
| CN-115003658-A | Compounds and their use in the treatment of alpha 1 Use against trypsin deficiency | Z因子有限公司 | 2022-09-02 | — | — | CN | disclosed |
| WO-2021116706-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY | Z Factor Limited (GB) | 2021-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230102488-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY | SERPINA2, SERPINB1, SERPINH1 | NAMPT 221/4885SMN1; SMN2 1752/4885ALDH1A1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.